Cancer stem cells: therapeutic implications and perspectives in cancer therapy  by Han, Lu et al.
Chinese Pharmaceutical AssociationInstitute of Materia Medica, Chinese Academy of Medical Sciences
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B 2013;3(2):65–752211-3835 & 2013 In
hosting by Elsevier B
http://dx.doi.org/10.1
Abbreviations: 5-F
ATP binding cassette
oligonucleotide; APC
basic ﬁbroblast grow
checkpoint kinase; C
DEAB, diethylamino
EGFR, epidermal gro
cell sorting; FGF2, ﬁ
secretase inhibitors; H
factor1a; HMGA2, h
heterotrimeric guanin
resistance transporte
nonobese diabetic/se
factor 4; PARP, poly
suberoylanilide hydro
interfering RNA(s);
HMG-box protein 2
factor-related apopto
nCorresponding au
E-mail address: x
Peer review under rwww.elsevier.com/locate/apsb
www.sciencedirect.comREVIEW
Cancer stem cells: therapeutic implications and perspectives
in cancer therapyLu Han, Sanjun Shi, Tao Gong, Zhirong Zhang, Xun SunnKey Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy,
Sichuan University, Chengdu 610041, China
Received 13 January 2013; revised 3 February 2013; accepted 12 February 2013KEY WORDS
Cancer stem cells;
Cancer therapy;stitute of Materia M
.V. All rights rese
016/j.apsb.2013.02
U, 5-ﬂuorouracil; A
superfamily subfam
, adenomatous pol
th factor; BMP4, b
ICs, cancer initiatin
benzaldehyde; EC
wth factor recepto
broblast growth fac
A, hyaluronic aci
igh mobility group
e nucleotide–bindi
r1; MMAF, mono
vere combined im
(ADP-ribose) poly
xamic acid; SCLC
SLGC, stem-like g
; SP, side-populati
sis induced ligand;
thor. Tel.: þ86 02
unsun22@gmail.c
esponsibility of InsAbstract The cancer stem cell (CSC) theory is gaining increasing attention from researchers and
has become an important focus of cancer research. According to the theory, a minority population
of cancer cells is capable of self-renewal and generation of differentiated progeny, termed cancer
stem cells (CSCs). Understanding the properties and characteristics of CSCs is key to future studyedica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and
rved.
.006
BC, ATP-binding cassette; ABCB1, ATP binding cassette superfamily subfamily B member 1; ABCG2,
ily G member 2; ALDH1, aldehyde dehydrogenase1; AML, acute myeloid leukemia; AMO, anti-miRNA
yposis coli; As2O3, arsenic trioxide; ASO, antisense oligonucleotide; ATRA, all-trans retinoic acid; bFGF,
one morphogenetic protein 4; CBP, CREB(cAMP response element binding protein) binding protein; Chk,
g cells; CRC-SCs, colorectal cancer stem cells; CSC(s), cancer stem cell(s); DDR, DNA damage response;
SCs, esophageal cancer stem cells; EGCG, (-)-epigallocatechin-3-gallate; EGF, epidermal growth factor;
r; EMT, epithelial-mesenchymal transition; ESA, epithelial-speciﬁc antigen; FACS, ﬂuorescence-activated
tor 2; Gli, glioma-associated oncogene homolog; G-CSF, Granulocyte colony-stimulating factor; GSIs, g-
d; HCS, high-content screening; HDAC, Histone deacetylase; Hh, Hedgehog; HIF-1a, hypoxia-inducible
AT-hook 2; HSCs, haematopoietic stem cells; IFNa, interferon-a; Lgr5, leucine-rich repeat–containing
ng protein–coupled receptor 5; LSCs, leukemia stem cells; MDR, multidrug resistance; MDR1, multidrug
methyl auristatin F; MSCs, mesenchymal stem cells; NICD, Notch intracellular domain; NOD/SCID,
munodeﬁciency; NSAID, nonsteroidal anti-inﬂammatory drugs; OCT-4, octamer-binding transcription
merase; PCR, polymerase chain reaction; PROM1, prominin-1; Ptch, patched; RA, retinoic acid; SAHA,
, small cell lung cancer; SFRPs, secreted frizzled-related proteins; SHh, sonic hedgehog; siRNA(s), small
lioma cells; SLNs, solid lipid nanoparticles; SMO, smoothened; SOX-2, sex-determing region Y-related
on; TCF, lymphoid enhancer factor; LEF, lymphoid enhancer-binding factor; TRAIL, tumor necrosis
TSCs, tumor stem cells; WIF1, Wnt inhibitory factor 1
8 85502307.
om (Xun Sun).
titute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.
Lu Han et al.66CSC marker;
CSC-targeted
mechanism;
Resistance;
Hedgehog;
Notch;
Wnt;
CSC niche;
Quiescent state;
miRNA expression;
Apoptosis;
Differentiationon cancer research, such as the isolation and identiﬁcation of CSCs, the cancer diagnosis, and the
cancer therapy. Standard oncology treatments, such as chemotherapy, radiotherapy and surgical
resection, can only shrink the bulk tumor and the tumor tends to relapse. Thus, therapeutic
strategies that focus on targeting CSCs and their microenvironmental niche address the ineffec-
tiveness of traditional cancer therapies to eradicate the CSCs that otherwise result in therapy
resistance. The combined use of traditional therapies with targeted CSC-speciﬁc agents may target
the whole cancer and offer a promising strategy for lasting treatment and even cure.
& 2013 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical
Association. Production and hosting by Elsevier B.V. All rights reserved.1. IntroductionSolid tumors similar to aberrantly developed organs and
tissues are composed of many types of cells including neo-
plastic cells, supporting vascular cells, inﬂammatory cells, and
ﬁbroblasts1. The majority of cells in bulk tumors have limited
self-renewal ability and are non-tumorigenic. Only a small
subpopulation of cancer cells are long-lived with the ability of
extensive self-renew and tumor formation. This small popula-
tion is called cancer stem cells (CSCs), or cancer initiating cells
(CICs), or tumor stem cells (TSCs)2,3.
The concept that cancer might evolve from a small popula-
tion of cells with stem cells properties was proposed about 150
years ago4,5. Huntly and Gilliland6 outlined the evolution of
cancer stem cell (CSC) research from 1855. The leukemis stem
cells (LSCs) were the ﬁrst to be described as CSCs in human
acute myeloid leukemia (AML)7. Bonnet and Dick8 demon-
strated that a subpopulation of CD34þ CD38AML cells
possessed LSCs with the capacities of differentiation, prolif-
eration and self-renewal, and were able to reconstitute a
heterogeneous cell population in NOD/SCID (nonobese dia-
betic/severe combined immunodeﬁciency) mice. With the
advances in stem cells biology and rapid development of
detecting technologies and rational animal models to measure
CSC properties, the CSC hypothesis is gaining validation5.
Schepers et al.9 demonstrated that Lgr5 (leucine-rich repeat–
containing heterotrimeric guanine nucleotide–binding protein–
coupled receptor 5) marked a subpopulation of adenoma cells
that fueled the growth of established intestinal adenomas,
revealing Lgr5þ stem cell activity in mouse intestinal adeno-
mas. Another study revealed that a quiescent subset of
endogenous glioma cells which related to CSCs propagates
glioblastoma growth10. Driessens et al.11 presented experi-
mental evidence for the existence of CSCs during unperturbed
solid tumor growth by clonal analysis. CSCs have also been
deﬁned in many other tumors including cancers of breast12,13,
pancreas14, prostate15, head and neck16, colon17,18, liver19,
bladder20 and lung21,22.
Most commonly used cancer therapies depend on che-
motherapy, radiation, or surgical resection solely or in combi-
nation. Schiller et al.23 found that neither the chemotherapy
regimens of cisplatin and gemcitabine, cisplatin and docetaxel,
or carboplatin and paclitaxel, nor the regimen of cisplatin and
paclitaxel offered a signiﬁcant advantage over other treat-
ments (e.g., mitomycin, ifosfamide and cisplatin) of advanced
non-small-cell lung cancer. On the other hand, Bonner et al.24found that when treated with high-dose radiotherapy plus
cetuximab, patents with local/regionally advanced head and
neck cancer survived longer than patients treated with radio-
therapy alone. Many other clinical trials have shown improve-
ments in cancer survival of combined therapy compared to
chemotherapy or radiotherapy25–28. However, the combined
therapy is not effective against all types of cancer, and the
severe toxicity cannot be ignored29. In addition, in later
rounds of therapy, the cancer tends to relapse and metastasize,
and often develops resistance to previous therapies29.
The standard oncology treatments have incomplete and
temporary effects that only shrink the tumor, and the tumor
tends to relapse mainly due to the multiple resistant mechanisms
existing in CSCs. Newer CSC-based therapies focus on elim-
inating the tumor initiating cells. In this review, we introduce the
basic information about CSCs including the deﬁnition, origina-
tion, and the main characteristics; compare different techniques
used to isolate and identify the minority of CSCs among the
bulk tumors; analyze the reasons for the failure of traditional
therapies (chemotherapy, radiotherapy) and the resistant
mechanisms inherent in CSCs and the micronvironment; and
discuss the multiple therapeutic implications of targeting CSCs.2. CSCs: deﬁnition, origination and characteristics
The widely accepted deﬁnition of a CSC is a cell within the
tumor that possesses the capacity to self-renew and to generate
the heterogeneous lineages of cancer cells that comprise the
tumor7,30. We also use the term ‘‘tumorigenic cell’’ or ‘‘tumor
initiating cell’’ to describe the pluripotent CSCs. Although
only a small subpopulation (o1%) of the overall cancer cells
have the ability to proliferate extensively and form new
tumors2,31, they are the crucial component leading to tumor
recurrence, therapy resistance, and metastasis5,32. CSCs may
undergo a symmetrical self-renewing cell division into two
identical daughter CSCs or an asymmetrical self-renewing cell
division into one daughter CSC and one differentiated
progenitor cell, resulting in number expansion of CSCs as
the tumor grows and to expand the tumor7.
Recent evidence suggests that CSCs may arise from normal
stem cells, progenitor cells, or more differentiated cells7,33 through
multiple mutations of genes as a result of their genomic instabil-
ity34 or oncogene-induced plasticity35. The genetic and epigenetic
instability of these cells may result in the accumulation of
mutations that enable them to acquire the ability of self-renewal
and tumorigenicity. The epithelial-mesenchymal transition (EMT)
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metastatic phenotype36. EMT is a series of steps, resulting in the
transformation of epithelial cells into ﬁbroblast-like and motile36,37
cells, and eventually the cancer cells acquire the ability to invade,
migrate, and disseminate38,39. CSCs and normal stem cells share
many similarities in terms of self-renewal, production of differ-
entiated progeny, expression of speciﬁc surface markers and
oncogenes, utilization of common signaling pathways, and the
importance of the stem cell niche2,32. CSCs are not synonymous
with normal stem cells. CSCs differ signiﬁcantly from normal stem
cells in their tumorigenic activity. CSCs can form tumors when
transplanted into animals, but normal stem cells cannot7.
Thus, we can deﬁne CSCs through these four key char-
acteristics: (a) self-renewal—the CSCs subpopulation can be
serially transplanted through multiple generations, indicating
the self-renewing capacity; (b) differentiation—pluripotent
CSCs can not only form tumorigenic daughter CSCs by
symmetrical cell division but also generate bulk populations
of non-tumorigenic cells by asymmetrical cell division; (c)
tumorigenicity—a small subpopulation of CSCs have tumori-
genic potential when transplanted into animals; and (d)
speciﬁc surface markers, by which the CSCs subpopulation
can be separated from the non-stem cells5,16,40. Therefore,
according to the deﬁnition and characteristics of CSCs, we can
conclude that the two hallmark features of CSCs are self-
renewal and lineage capacity.3. CSCs: isolation and identiﬁcation
The isolation of the minority of CSCs from mass tumor tissues
or cell lines and the identiﬁcation of the stem-like CSCs by
diverse methods will be quite important to researches of tumor
initiation, tumor development, and tumor diagnostics and
therapeutics. Since CSCs and normal stem cells have much in
common, we can also use the stem cell properties, such as the
expression of speciﬁc surface markers, to isolate and identify
CSCs. Up to now, we usually take advantage of these features,
namely, the sphere forming ability in non-adherent medium,
dye exclusion ability which is because of the over-expression of
efﬂux transporters, expression of speciﬁc cell surface markers
and signaling pathways, intracellular enzyme activity, and
clonogenicity, to isolate the CSCs3,36,41,42. Thus, there are
several in vitro assays to identify CSCs, such as sphere forming
assays41,43, Hoechst dye exclusion (SP cells)16,33, detection
enzymatic activity of aldehyde dehydrogenase1 (ALDH1)44,45,
detection of surface markers3,7,16, signaling pathway identiﬁ-
cation46, serial colony-forming unit assays (replating assays)33,
lable-retention assays7, and migration assays39,47. However,
in vitro assays alone are not enough to demonstrate that the
cells we detect are CSCs, for normal stem cells or progenitors
may have the same characteristics as CSCs and these assays
cannot show tumor propagation. Thus in vivo assays are
regarded as the gold standard, including serial transplantation
in animal models, which can complement and enhance the
ability of in vitro assays to identify CSCs7. However, improved
and optimized methods need to be developed to identify CSCs.
3.1. Stem cell markers
The main markers used for isolation, identiﬁcation and puriﬁca-
tion of CSCs include surface cell-adhesion molecules (e.g., CD133,CD24, hyaluronic acid (HA) receptor CD44), cytoprotective
enzymes (such as aldehyde dehydrogenase, ALDH), transcription
factors (e.g., OCT-4, SOX-2), and drug-efﬂux pumps (e.g., ATP-
binding cassette (ABC) drug transporters and multidrug resis-
tance transporter1, MDR1). Flow cytometry analysis,
ﬂuorescence-activated cell sorting (FACS) analysis, polymerase
chain reaction (PCR) analysis and immunoﬂuorescent staining
analysis are based on these speciﬁc markers of CSCs and
are widely used to isolate, purify, and characterize the
CSCs16,21,43,48,49.
The most widely used method for identifying CSCs is based
on speciﬁc cell surface markers3,7,37, such as CD133, CD24
and CD44. However, the surface markers of CSCs or normal
stem cells in one organ or tissue are frequently not completely
shared with the markers of CSCs or normal stem cells in other
organs or tissues. For example, Al-Hajj et al.12 demonstrated
that in human breast cancer, CD44þCD24 phenotype cells
were tumorigenic, but the alternate phenotypes were unable to
form tumors. While Li et al.50 showed that in human
pancreatic cancer cells, CD44þCD24þESAþ (ESA: epithelial-
speciﬁc antigen) phenotype was much more tumorigenic than
nontumorigenic cancer cells. Yang et al.19 also suggested that
CD45CD90þCD44þ could be used as a marker for human
liver cancer and as a target for the diagnosis and therapy of
this malignancy. Furthermore, the surface markers that are
used to isolate or identify CSCs from many malignant tissues
are not expressed by CSCs exclusively, because many normal
stem cells and even some normal tissues can express the same
markers. Fox et al.51 demonstrated that normal human tissues
could express different CD44 isoforms, such as the normal
epithelial tissues as well as some tumors could express a wide
range of variants at high levels. Moreover, whether a surface
marker can be used to isolate or identify stem cells from a
speciﬁc tissue is environment dependent, meaning that the
marker expression may change with the context of the stem
cells7.
Thus, the use of surface marker expression solely is
insufﬁcient to identify CSCs. Detection of surface markers
must be associated with other functional assays, such as the
sphere-forming assay in serum-free medium or soft agar
medium, detection of enzymatic activity of ALDH1, and
measurement of the expression of speciﬁc CSC genes to
provide persuasive evidence for the existence of CSCs.3.2. Sphere forming assays
One important property of CSCs, as well as normal stem cells,
is to form spheres or grow into colonies in serum-free medium
or in soft agar medium. To show aggregation and prolifera-
tion of stem cells in vitro, cells are harvested from tumor
specimens and suspended at a low density in serum-free
medium supplemented with epidermal growth factor (EGF)
and basic ﬁbroblast growth factor (bFGF), and the colony-
forming capacity can be determined in soft agar media. Qiu
et al.21 demonstrated that small cell lung cancer (SCLC) cell
lines H446 cells were proliferative and capable of self-renewal
in a deﬁned serum-free medium, and then they found that the
sphere-derived cells had increased in vitro clonogenic and
in vivo tumorigenic potentials as well as drug-resistance
properties, suggesting the CSC populations in H446 cells.
Zhang et al.42 and Ghani et al.41 also took advantage of
Lu Han et al.68the property of stem cells to form spheres or colonies in non-
adherent culture to determine whether the cells obtained from
tumors were stem-like cells with self-renewal capacity. Dou
et al.43 used both serum-free culture assay and colony-forming
assay to measure the proliferative activity and clone-forming
capability of tumor cells.
However, despite these merits, these in vitro assays have
many limitations. For example, it is difﬁcult to conﬁrm the
clonality (signal cell origin) of in vitro assays. Moreover, the
cells are under selection pressure exerted by the culture
conditions, leading to selection of only the cell populations
that are able to survive and proliferate under such speciﬁc
conditions33. In addition, in vitro assays measure ex vivo
proliferation instead of true self-renewal and they cannot
show the tumor formation ability of CSCs. To overcome
these drawbacks, the results of in vitro assays must be
conﬁrmed by in vivo assay.
3.3. Transplantation assays
The hallmarks of any stem cell are the ability to self-renew and
the capacity to differentiate; thus, assays that measure CSCs
activity should emphasize self-renewal as well as tumor
propagation, and the gold standard assay which fulﬁlls these
two criteria for identifying CSCs is serial transplantation in
animal models7. To identify CSCs in human tumors using
serial transplantation assays, tumor cells are transplanted into
the immunocompromised (typically NOD/SCID) mice, mon-
itoring the mice at various time points for tumor growth; then,
xenograft tumors or primary human tumors must be iso-
lated from the mice and implanted into other immunocom-
promised mice to show self-renewal and tumor formation
capacities7,45,50,52.
However, it is reported that a relatively large number of
cancer cells are required to initiate tumor growth when
xenotransplanted into animal models5,30,36. This may be
because only a minor population of cancer cells are capable
of self-renewal and tumor-formation; these cancer cells may be
inefﬁcient to initiate tumor growth, and, in addition, it is likely
that the cancer cells are in a foreign microenvironment that
lacks the speciﬁc signals for the survival and development
when xenotransplanted into immunodeﬁcient mice. It is thus
necessary to sort the cancer cells based on the speciﬁc markers
of CSCs, and select stem-like cells for higher tumor obtaining
rates.4. CSC-targeted mechanisms and implications
The traditional and mainstream therapies to treat cancer are
chemotherapy and radiotherapy, although they face many
obstacles such as systemic or local toxicity and drug resistance.
The most popular anti-cancer agents consist of paclitaxel,
doxorubicin and cisplatin, and so on. Though these agents
are capable of high cytotoxicity that kills the bulk of tumor and
are commonly used in clinic, they are non-targeting and often
result in tumor recurrence because of drug resistance1,53. For
many cancers, ionizing radiation represents the best non-
invasive therapy with beneﬁts in overall survival, but it may
also cause therapy failure owing to the existence of CSCs30,54,55.
Although CSCs account for only a small part of the bulk
tumors, they are the cardinal reason leading to therapeuticresistance. The mechanisms of CSCs that contribute to ther-
apeutic resistance include relative dormancy/slow cell cycle
kinetics, high capacity for DNA repair, high expression of
multiple drug resistance membrane transporters (e.g., ABC
transporters), high expression of anti-apoptosis proteins, and
the microenvironment (hypoxia, acidosis, etc.)1,29,37,56,57. Both
tumor recurrence and serious side effects contribute to the
failure of traditional therapies. Thus, traditional chemo-
radiotherapy should be combined with new strategies targeting
CSCs to prevent tumor relapse and to provide a high-efﬁcient
and low-toxic treatment for cancer therapy.
4.1. Targeting the molecular signaling pathways
Signaling pathways are essential for normal stem cells related
to self-renewal, proliferation and differentiation; however, the
dysregulation or aberrant activation of these key pathways
may result in the formation of CSCs which induce tumorigen-
esis. These important signaling pathways consist of Hedgehog
(Hh), Notch, Wnt/b-catenin, high mobility group AT-hook 2
(HMGA2), Bcl-2, Bmi-1, etc. The most studied and character-
ized pathways are Hh, Notch, Wnt/b-catenin, which are
responsible for the formation of CSCs46,58–60. Therefore,
targeting these aberrant signaling pathways that are important
for the formation of CSCs offers a new strategy for cancer
therapy.
4.1.1. The Hedgehog signaling pathway
The Hedgehog (Hh) pathway is essential for the maintenance
of stem cells and plays a crucial role in development and
patterning during mammalian embryogenesis61. When Hh
protein binds to the transmembrane protein called patched
(Ptch), the Hh pathway is activated59, resulting in the regula-
tion of target genes which are involved in many cellular
functions including proliferation, survival, metastasis, and
pathway auto-regulation58,61,62. The aberrant activation of
the Hh pathway may lead to deformations in development
as well as contribute to tumorigenesis in various human
cancers46,63.
Recent researches have suggested that the Hh pathway is
essential for the maintenance of CSCs in various human
cancers including pancreatic cancer, gastric cancer, colorectal
cancer, and so on60,64–66, and it is also responsible for
treatment resistance of cancer cells67. Thus, inhibitors that
obstruct any step of the Hh signaling pathway may result in
depletion of CSCs and overcome the treatment resistance. Xia
et al.68 showed the signaling pathways in pancreatic CSCs
include the Hh pathway, and introduced inhibitors targeting
Hh pathway for cancer therapy. Most drugs for Hh pathway
therapeutics inhibit the signaling molecule smoothened
(SMO), like cyclopamine and GDC-0449 (Vismodegib)69,
but they would be ineffective against tumors that harbor
molecular lesions that lie downstream of SMO. So other
agents such as arsenic trioxide (As2O3) which inhibits
glioma-associated oncogene homolog (Gli) proteins are used
in combination with SMO inhibitors63. Tang et al.66 found
that ()-epigallocatechin-3-gallate (EGCG) inhibited the com-
ponents of sonic hedgehog (SHh) pathway (SMO, Ptch, Gli1
and Gli2) and Gli transcriptional activity, and the combina-
tion of quercetin with EGCG had synergistic inhibitory effects
on self-renewal capacity of CSCs through attenuation of TCF/
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targeting SHh pathway might improve the therapeutic out-
comes of patients with pancreatic cancer by targeting CSCs.4.1.2. The Notch signaling pathway
The Notch signaling pathway plays crucial roles in cell-cell
communication and in multiple cell fate decisions during
embryonic development and adult life70,71. The Notch path-
way is activated through ligand-receptor interactions of four
receptors (Notch-1–Notch-4) and ﬁve Notch ligands (Delta-
like1, 3, 4 and Jagged1, 2)71, resulting in the expression of
multiple target genes2,59. The Notch pathway is involved in
stem cell proliferation, differentiation, and apoptosis, but its
role in tumorigenesis is context-dependent and can be either
oncogenic or oncosuppressive71. Speciﬁcally, Notch functions
as an oncogenic protein in most human cancers including
cervical, lung, colon, head and neck, prostate, pancreatic
cancer, etc., while it may act as tumor suppressor in skin
cancer, hepatocellular carcinoma, and SCLC68,72–74.
The Notch pathway is often over-activated in a variety of
cancers, and it is believed to be a target to eliminate CSCs75–77.
Blocking the proteolytic process which is crucial for the
formation of Notch intracellular domain (NICD) is one of
the most efﬁcient methods to inhibit Notch signaling path-
way59. Fan et al.78 used g-secretase inhibitors (GSIs) to block
Notch pathway in glioblastoma, resulting in the reduced
neurosphere growth and clonogenicity in vitro; the reduced
expression of putative CSCs markers, in addition, the reduced
tumor growth in vivo. Thus, they suggested that GSIs which
block Notch pathway might be useful chemotherapeutic
reagents to target CSCs in malignant gliomas. Kondratyev
et al.79 also reported that GSI MRK-003 eliminated cancer
stem-like cells and inhibited the self-renewal and proliferation
of breast CSCs. However, GSIs are nonselective drugs because
they are able to block the cleavage of all four Notch ligands
and various g-secretase substrates; thus, ‘natural agents’ that
are non-toxic to humans are needed to overcome the limita-
tions of GSIs75.4.1.3. The Wnt signaling pathway
The Wnt signaling pathway is another developmental pathway
involved in multiple biological processes including embryo-
genesis, development, cell proliferation, survival and differ-
entiation68,80. The canonical Wnt/b-catenin signaling pathway
is by far the best characterized among Wnt pathways58. Wnt/
b-catenin signaling is initiated when a Wnt ligand (secreted
glycoprotein) binds to the cell membrane co-receptors, result-
ing in the activation of target genes80. The canonical Wnt
signaling pathway plays an important role in self-renewal and
maintenance of stem cells and CSCs of tissues such as skin,
intestine and mammary gland81,82. However, oncogenic muta-
tions of b-catenin, or inactivating mutations of APC (adeno-
matous polyposis coli) tumor suppressor may result in the
dysregulation of Wnt/b-catenin pathway in cancer cells or
CSCs, which induces neoplastic proliferation83.
The Wnt signaling pathway can be inhibited by Wnt
inhibitory factors, Wnt antagonists and conditional knockout
of b-catenin. Extracellular molecules antagonize the Wnt
signaling pathway by preventing ligand-receptor interac-
tions84. Inhibitors of the Wnt/b-catenin signaling pathway
can be divided into two classes: small-molecule inhibitors andbiologic inhibitors85. Small-molecule inhibitors include exist-
ing drugs such as nonsteroidal anti-inﬂammatory drugs
(NSAID) or natural compounds, and molecular-targeted
agents such as the cAMP response-element binding protein
binding protein (CBP)/b-catenin antagonist ICG-001. These
inhibitors can interfere with Wnt pathway by inhibiting the
Wnt target enzyme cyclooxygenase 2 (e.g. aspirin, indometha-
cin), by activating E-cadherin (e.g. vitamins A and D deriva-
tives), or by promoting degradation of TCF (e.g. celecoxib).
Biologic inhibitors include monoclonal antibodies, small
interfering RNAs (siRNAs), and recombinant proteins against
Wnt1/2, WIF1(Wnt inhibitory factor 1) and SFRPs (secreted
frizzled-related proteins)80,81,85. Takahashi-Yanaga et al.85
showed that CBP/b-catenin antagonist ICG-001 was able to
target and eliminate drug-resistant leukemic stem cells both
in vivo and in vitro. Teng et al.86 knocked down the expression
of b-catenin using RNA interference technology to inhibit
Wnt signaling, resulting in down-regulation of many CSC
properties, such as the Wnt target gene cyclin D1, prolifera-
tion, clone formation, migration, drug resistance, as well as
the expression of OCT-4. They demonstrated that canonical
Wnt signaling plays an important role in lung CSC properties.
Therefore, targeting Wnt signaling pathway in CSCs is
another approach for cancer therapy.
Although dysregulation of these signaling pathways is
found in CSCs, they express normally in normal stem cells.
Thus, agents targeting these signaling pathways not only can
target the CSCs but also inﬂuence normal stem cells, inducing
unwanted effects. In this regard, targeting agents should be
modiﬁed or should be combined with other CSC-targeting
therapies to improve their speciﬁcity.
4.2. Targeting CSCs markers
The markers used to isolate, identify and enrich CSCs are also
ideal targets for cancer therapy. Targeting cytotoxic drugs to
CSCs with the help of stem cell surface markers provides a
useful method to treat cancer. Also, the use of inhibitors
targeting drug-detoxify enzymes, drug-efﬂux pumps, or tran-
scription factors of CSCs represents a novel approach to target
the CSCs and reduce cancer recurrence and metastasis.
4.2.1. Targeting surface markers
CSCs in various tumors highly express speciﬁc surface markers,
such as CD133 in hepatocellular and gastric cancer87,
CD44þCD24þESAþ in pancreatic CSCs50, CD9þCD24þCD26þ
in human malignant mesothelioma CSCs41. Among these mar-
kers, CD133 is considered the most important CSC-associated
marker identiﬁed so far88.
CD133 (prominin-1, PROM1) which was discovered as a
marker of primitive haematopoietic and neural stem cells, is a
pentaspan transmembrane glycoprotein overexpressed in both
humans and mice tumors89. Some evidence has suggested that
CD133þ CSCs display strong resistance to chemotherapy and
radiotherapy54,90. Todaro et al.18 identiﬁed and characterized
stem-like cells from colon carcinomas using CD133, and
revealed that CD133þ cells grew in undifferentiated tumor
spheroids in vitro and initiated tumor growth in immunodeﬁ-
cient mice. In addition, the CD133þ stem-like cells survived
standard chemotherapeutic treatment with oxaliplatin and
5-ﬂuorouracil (5-FU). Rappa et al.91 investigated that down-
Lu Han et al.70regulation of CD133 using short hairpin RNAs in human
metastatic melanoma leading to slower cell growth, reduced
cell motility, and decreased ability to form spheroids, and
reduced capacity of metastasis, particularly to the spinal cord.
Then they used monoclonal antibodies directed against two
different epitopes of the CD133 protein to treat FEMX-I cells
(human malignant melanoma cells), and found a speciﬁc,
dose-dependent cytotoxic effect in FEMX-I cells. It was
concluded that CD133 was not only a CSC marker but might
also be an important therapeutic target for many CD133-
expressing cancer types including metastatic melanoma. In
another study, Smith et al.87 conjugated a murine anti-human
CD133 antibody (AC133) to a potent cytotoxic drug (mono-
methyl auristatin F, MMAF), and found that the conjugates
effectively inhibited the growth of Hep3B hepatocellular and
KATO III gastric cancer cells in vitro. It suggests that CD133
is a potential therapeutic target for antibody-drug conjugates,
and anti-CD133 antibody-drug conjugates may be a thera-
peutic method to eliminate CD133þ tumors.4.2.2. Targeting drug-detoxify enzymes
ALDH are a group of NAD(P)þ-dependent enzymes that
catalyze the oxidization of aldehydes into carboxylic acids2.
Certain isoenzymes (e.g. ALDH1) of ALDH superfamily not
only act as markers for both normal and CSCs but may also play
important functional roles in self-protection, differentiation and
expansion. Thus ALDH can act as drug-detoxifying enzymes and
be responsible for therapeutic resistance45,92,93. In the Aldeﬂuor
assay, ALDH-activated ﬂuorescent substrate is used as a marker
for measuring and isolating normal and CSCs with high ALDH
activity33. Croker et al.94 identiﬁed a subpopulation of stem-like
ALDHhiCD44þ cells in human breast cancer cell lines. They
demonstrated that ALDHhiCD44þ cells were more resistant to
standard cancer therapy such as chemotherapy (doxorubicin/
paclitaxel) or radiotherapy, and that inhibiting ALDH activity of
cell populations through speciﬁc ALDH inhibitor diethylamino-
benzaldehyde (DEAB) or all-trans retinoic acid (ATRA) sensi-
tized these cells to treatment. However, only DEAB had a long-
term sensitization effect, indicating that selectively blocking
ALDH activity played a key role in targeting the resistant cells
and revealed a promising target for cancer treatment.4.2.3. Targeting drug-efﬂux pumps
ABC drug transporters are overexpressed in both normal stem
cells and many TSCs as efﬂux pumps to protect stem cells
from xenobiotic toxins22,95–97. ABCG2 (also known as
BCRP), an important member of ABC transporter family, is
regarded as a potential marker of CSCs as well as a mechan-
ism in multidrug resistance (MDR)2,33. ABCG2 is an impor-
tant determinant of the side-population (SP) phenotype. SP
cells show many features of CSCs with regard to self-renewal,
lineage capacity, tumorigenicity, and the expression of CSC
markers and stem cell genes, and can be found in various
tumor cell lines; thus, SP cells can be assumed as CSCs33,98.
Xia et al.99 developed an image-based high-content screening
(HCS) system to speciﬁcally identify 12 potent high drug efﬂux
cancer cell (HDECC) inhibitors from 1280 pharmacologically
active compounds. Then through in vitro assays and in vivo
assays, they showed that these inhibitors were able to over-
come MDR by inhibiting SP and increase the efﬁcacy of
chemotherapy, or reduce the tumorigenicity of lung cancercells possibly by affecting stem-like cancer cells. Fong et al.100
used Hoechst 33,342 dye and ﬂow cytometry to examine the
inhibition effect of curcumin on the rat C6 glioma cell line.
The dye-exclusion assay indicated the activity present in SP
cells, and they observed a decrease in SP cells after daily
treatment of curcumin, indicating that curcumin might be
active against brain CSCs and that phytochemicals could offer
therapeutic potentials for targeting CSCs. It is worth noting
that ABC transporters are highly expressed not only in CSCs
but also in normal stem cells; moreover, ABCG2 and ABCB1
are important in maintaining the blood-brain barrier, so ideal
therapy using inhibitors should be designed to specially target
ABC transporters of CSCs but spare normal stem cells.
Therefore, the combined use of inhibitors which specially
target ABC drug transporters of CSCs and chemotherapy
drugs offers a powerful and selective strategy to eradicate
CSCs95.
As we have mentioned above, different kinds of CSCs may not
share the same markers, and these markers are expressed not only
by CSCs but also by other cells such as normal stem cells.
Therefore, strategies targeting these markers should consider
these conditions, and ﬁnd more speciﬁc targeting methods.4.3. Targeting CSC niche and the quiescent state
Normal stem cells reside in a ‘‘stem cell niche’’ which provides
necessary signals for the maintenance of stem cell proper-
ties101. Likewise, CSCs require a similar microenvironment,
termed CSC niche, which provides appropriate signals (neces-
sary signaling pathways) to regulate self-renewal and the
normal homeostatic processes such as inﬂammation, EMT,
hypoxia and angiogenesis101. Vermeulen et al.102 found that
Wnt activity functionally designated the colon CSC popula-
tion, and proposed that the ‘‘stemness’’ of colon cancer cells
was in part orchestrated by the microenvironment. Calabrese
et al.103 proposed that the brain tumor microvasculature
formed a niche that was critical for the maintenance of CSCs,
and the vascular niches were important targets for therapeutic
approaches. Hypoxia plays a key role in tumor progression
and hypoxic tumor microenvironment also controls CSCs104.
Morrison et al.29 speculated that antiangiogenic therapies
might induce CSC niche hypoxia, conferring radioresistance
to the CSCs. Conley et al105. demonstrated that antiangiogenic
agents such as sunitinib and bevacizumab could drive breast
CSC stimulation by generating intratumoral hypoxia. Thus,
they suggested that these antiangiogenic agents should be
combined with CSC-targeted drugs. In addition, Zhong
et al.106 suggested that the inhibitors such as LY294002 and
rapamycin for hypoxia-inducible factor1a (HIF-1a) could
provide a basis for therapeutic efﬁcacy. Therefore, targeting
the CSC niche in combination with chemotherapy can provide
a promising strategy for eradicating CSCs.
CSCs are resistant to traditional chemotherapy, because
most of the current anticancer drugs target tumor growth by
inhibiting DNA synthesis or cell division of actively divid-
ing cancer cells; however, CSCs are frequently in a quiescent
state107. Quiescence physiologically protects adult stem cells
from harmful insults and prevents the exhaustion of their
replicative potential58. CSCs are postulated to contribute to
tumor dormancy and usually have a slow cell cycle kinetics
which protects CSCs from chemo-radiotherapy108. Thus,
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receptors and signaling pathways within the CSC niche can
inhibit CSC functions of tumor initiation and metastasis101.
Inducing dormant CSCs to enter the cell cycle provides an
alternative way to restore chemo- and radio-sensitivity.
Recent studies have revealed that some cytokines such as
interferon-a (IFNa) and granulocyte-colony stimulating
factor (G-CSF), or As2O3 can efﬁciently promote the
cycling of normal haematopoietic stem cells (HSCs) and
LSCs109. Therefore, combination of IFNa, G-CSF, As2O3
with chemotherapeutic agents may effectively target the
dormant LSCs109.
Targeting the stem cell niche can exhaust the source of
nutrition and change the essential signals needed by CSCs. On
the other hand, it can also inﬂuence the normal stem cell
niche, or disrupt the levels of signals for normal cells. Thus,
more sophisticated strategies are needed to overcome the
shortcomings of the existing methods.
4.4. Manipulation of miRNA expression
MicroRNAs (miRNAs) are approximately 21-nucleotide long
non-coding RNAs that regulate self-renewal, differentiation, and
division of cells via post-transcriptional gene silencing110. miR-
NAs can act as both tumor suppressors and oncogenes, both of
which are deregulated in cancers111,112. For example, microRNA-
34a (miR-34a) is a direct target of tumor suppressor gene p53 and
down-regulated in many cancers113. MiR-34a is a tumor sup-
pressor that acts by targeting multiple oncogenes such as c-Met,
Notch-1, Notch-2 and CDK6 and by inducing the differentiation
of CSCs in brain tumors and glioma stem cells114,115. Liu et al.116
showed that CD44 was a direct and functional target of miR-34a
and miR-34a was a key negative regulator of CD44þ prostate
cancer cells, suggesting that miR-34a was a novel therapeutic
agent against prostate CSCs. miR-21 and miR-205 are highly
expressed and predicted to act as oncogenes by targeting the
tumor suppressor genes in head and neck cancer cell lines111,117. A
powerful technique for therapeutic targeting of miRNAs, as well
as for miRNA functionalization both in vitro and in vivo is
antisense oligonucleotide (ASO) inhibition118. Shi et al.119 pre-
pared solid lipid nanoparticles (SLNs) loading with anti-miRNA
oligonucleotide (AMO) for suppressing microRNA-21 functions.
Then they demonstrated that the cationic AMO-loaded SLNs
had high antisense efﬁciency of miR-21 and subsequently
decreased the proliferation, migration and invasion of human
lung cancer A549 cells. Nozawa et al.120 showed that siRNA
could downregulate the expression of epidermal growth factor
receptor (EGFR) and inhibit cell growth of head and neck
squamous cell carcinoma (HNSCC), and EGFR siRNA signiﬁ-
cantly enhanced the chemosensetivity of HNSCC to cisplatin, 5-
FU and docetaxel. Therefore, microRNA-based therapeutics that
can rectify the aberrant transcript levels of cancer cells and
especially target CSCs are of great potential in cancer therapy.
4.5. Induction of CSCs apoptosis
Apoptosis governs tissue development and homeostatic bal-
ance through a complex network of molecules that mediate
death and survival signals, and it is also critical for maintain-
ing normal cell physiological processes57,121. Dysregulation of
apoptotic mechanisms contributes to cancer development,progression, as well as CSC resistance. These mechanisms
include impaired apoptotic machinery, increased DNA damage
repair after radiotherapy and chemotherapy, altered cell cycle
checkpoint control, and upregulation of MDR proteins57. There-
fore, manipulating the apoptotic machinery to induce apoptosis
of CSCs shows great potential to eradicate CSCs for cancer
therapy. Many compounds induce apoptosis by targeting the
intrinsic and extrinsic apoptosis pathways. For example, NK-kB
is a transcription factor that inhibits apoptosis by increasing the
expression of survival factor121. Hexum et al.122 synthesized
several bicyclic cyclohexenones which were able to inhibit NK-
kB signaling by inhibiting NK-kB-induced IL-8 expression and
exhibit antiproliferative activity against A549 cells (a human lung
adenocarcinoma epithelial cell line), CCRF-CEM cells (a human
T cell lymphoblast-like cell line) and DU-145 cells (a human
prostate carcinoma cell line). Tumor necrosis factor-related
apoptosis induced ligand (TRAIL) is one of the pro-apoptotic
proteins that induce apoptosis in a wide range of cancer types121.
The combined treatment with recombinant TRAIL and the Akt
signaling inhibitor perifosine showed a synergistic pro-apoptotic
activity against AML cells123. The delivery of TRAIL via
mesenchymal stem cells (MSCs) is a new targeting therapy.
MSCs are emerging as promising anti-cancer agents with the
property of inherent tumor-trophic migratory which allow them
to serve as vehicles for anticancer gene delivery124. Loebinger
et al.125 showed that TRAIL-expressing MSCs migrated to
tumors and reduced the growth of primary cancers and metas-
tasis, and TRAIL-expressing MSCs combined with mitoxan-
trone chemotherapy had a synergistic effect in apoptotic
induction of putative CSCs. The expression of many antiapop-
totic proteins is also responsible for CSC resistance. Todaro
et al.18 revealed that CD133þ CSCs from colon carcinomas
could produce and use IL-4 to protect them from apoptosis, and
treatment with an IL-4Ra antagonist or anti-IL-4 neutralizing
antibody signiﬁcantly enhanced the sensitivity of CD133þ cells to
standard chemotherapeutic drugs (oxaliplatin and 5-FU).
Improperly activated DNA damage repair pathways enable
cancer cells to survive chemo- and radiotherapy. DNA repair
pathways compete with apoptotic signaling to determine the
fate of damaged cells58. However, CSCs prone to enhanced
DNA repair capacity and anti-apoptosis pathways to avoid
cell death. Chen et al.126 demonstrated that esophageal cancer
stem cells (ECSCs) employed attenuated DNA damage
response (DDR) and decreased DNA repair potential to
handle severe genomic insults when treated with DNA dama-
ging agents. Marie et al.127 also found that when exposed to
ionizing radiation, epidermoid carcinoma cells showed rapid
DNA repair mediated by ﬁbroblast growth factor 2 (FGF2).
Thus, agents that interfere with DNA repair have great
therapeutic potential. Poly(ADP-ribose) polymerase (PARP)
inhibitors potentiate the activity of DNA-damaging agents
and radiation for the treatment of many cancers58,128. The
combined use of novel inhibitors of DNA-dependent protein
kinase and PARP-1 can inhibit DNA repair and act as potent
radiosensitizers129. In addition, the pharmacological abroga-
tion of checkpoint kinase (Chk) 1 could selectively kill cancer
cells with p53 defects58. Bao et al.130 suggested that a speciﬁc
inhibitor of the Chk1 and Chk2 could reverse the radio-
resistance of CD133þ glioma stem cells.
Despite the effectiveness of inducing apoptosis, therapies should
avoid inducing apoptosis in normal cells, and should improve the
speciﬁcity and effectiveness in inducing CSCs apoptosis.
Fig. 1 Therapeutic implications. The traditional cancer therapies kill differentiated cancer cells but fail to target CSCs, resulting in
cancer relapse. However, CSC-targeted therapies can eliminate or differentiate the CSCs, and the remaining and resulting differentiated
cancer cells will die thereafter. But it is promising to combine CSC-targeted therapies and traditional therapies for depleting CSCs as well
as killing differentiated cancer cells, this combination therapy may have the beneﬁts of increased efﬁcacy and quick action.
Lu Han et al.724.6. Induction of CSC differentiation
Apart from elimination therapies noted above that increase the
efﬁcacy of cancer therapy, another way to control tumor
progression is to induce differentiation of CSCs (Fig. 1).
Differentiation therapy could force CSCs to differentiate termin-
ally and lose their self-renewal property70. Although many agents
have been studied in differentiation therapy, only two kinds of
anticancer drugs can affect cancer cell differentiation: retinoic
acids and drugs targeting tumor epigenetic changes131. Retinoic
acid (RA, Vitamin A), and its analogs (retinoid) can subvert the
malignant progression process through signal modulation
mediated mainly by retinoid receptors70,131. Campos et al.132
revealed that ATRA induced differentiation of stem-like glioma
cells (SLGC) and showed an antitumor effect both in vitro and
in vivo. Their research demonstrates that differentiation therapy
by retinoic acids may target the CSCs in glioblastoma. Ginestier
et al.133 demonstrated that modulation of the retinoid signaling
might be sufﬁcient to promote self-renewal or induce differentia-
tion of breast CSCs. They also indicated that ATRA treatment
induced the differentiation of breast CSCs, resulting in a
signiﬁcant decrease of the breast CSC population. These results
suggested that ATRA might be a therapeutic strategy for
targeting breast CSCs. Histone deacetylase (HDAC) inhibitors,
suberoylanilide hydroxamic acid (SAHA) can cause growth
arrest, differentiation, and/or apoptosis of many tumor types in
vivo and in vitro, and has been used exprerimentally in cancer
differentiation therapy70,134. Butler et al.135 found that hydro-
xamic acid-based hybrid polar compounds such as SAHA
suppressed the growth of human prostate cancer cells, and
suggested that these compounds could be useful and relatively
nontoxic agents for the treatment of prostate carcinoma. The
combined use of differentiation-inducing agents and chemother-
apy represents an effective approach to eliminate the CSCs.
Lombardo et al.136 demonstrated that bone morphogenetic
protein 4 (BMP4), which could promote normal colonic stemcells differentiation, was able to promote terminal differentiation,
to induce apoptosis of chemoresistant colorectal cancer stem cells
(CRC-SCs), as well as enhance the chemosensitization of CRC-
SCs to 5-ﬂuorouracil and oxaliplatin, suggesting a therapeutic
target against CSCs in advanced colorectal tumors.
Inducing CSC differentiation provides an alternative way to
deplete cancer cells, while agents such as ATRA, SAHA may
cause normal stem cells differentiation or other side effects.
Therefore, toxicity studies should be done before the further
application of the drugs.5. Conclusion and perspectives
According to the CSC theory, CSCs are responsible not only
for tumor initiation, development, and metastasis, but also for
therapeutic resistance. Standard oncology treatments such as
chemotherapy and radiotherapy can only shrink the tumors by
killing the active tumor cells but miss the quiescent CSCs that
lead to resistance and relapse, and may even enrich CSCs for a
more resistant state30,53. These traditional approaches usually
include systemic or local toxicity. Thus, new treatments
targeting CSCs are necessary for improving patient survival
rate and elongating life span. In this review, we discussed some
strategies for cancer therapy which can directly eliminate or
differentiate CSCs. These targeting strategies provide novel
and promising approaches for CSC-targeted cancer therapy.
Furthermore, the combination of targeted therapies directly
eliminating or differentiating CSCs with established therapies
may have a synergistic action and increased efﬁcacy in cancer
treatment. There is great need to develop new methods or
improve the existing methods to isolate and identify CSCs.
Since CSCs and normal stem cells share many properties,
targeting CSCs may unfortunately affect normal stem cells.
Thus, more precise targeting therapies which can selectively
target CSCs but spare normal stem cells are greatly needed.
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